Kate Haviland
2017
In 2017, Kate Haviland earned a total compensation of $1.5M as Chief Business Officer at Blueprint Medicines, a 11% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $141,027 |
|---|---|
| Option Awards | $962,112 |
| Salary | $353,451 |
| Other | $8,100 |
| Total | $1,464,690 |
Haviland received $962.1K in option awards, accounting for 66% of the total pay in 2017.
Haviland also received $141K in non-equity incentive plan, $353.5K in salary and $8.1K in other compensation.
Rankings
In 2017, Kate Haviland's compensation ranked 7,103rd out of 14,666 executives tracked by ExecPay. In other words, Haviland earned more than 51.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,103 out of 14,666 | 52nd |
Division Manufacturing | 2,636 out of 5,772 | 54th |
Major group Chemicals And Allied Products | 859 out of 2,075 | 59th |
Industry group Drugs | 668 out of 1,731 | 61st |
Industry Pharmaceutical Preparations | 522 out of 1,333 | 61st |
Source: SEC filing on April 27, 2018.
Haviland's colleagues
We found six more compensation records of executives who worked with Kate Haviland at Blueprint Medicines in 2017.
2017
Jeffrey Albers
Blueprint Medicines
Chief Executive Officer
2017
Christopher Murray
Blueprint Medicines
Senior Vice President, Technical Operations
2017
Anthony Boral
Blueprint Medicines
Chief Medical Officer
2017
Kathryn Haviland
Blueprint Medicines
Chief Operating Officer
2017
Michael Landsittel
Blueprint Medicines
Vice President, Finance
2017
Tracey McCain
Blueprint Medicines